Molbio Diagnostics IPO is a mainboard IPO raising ₹940 Cr at ₹768 – ₹807 a share. It listed on 17 Aug 2026 at ₹980, +21.4% against its issue price of ₹807, and trades at ₹1,407 today (+74.3% since issue). It was subscribed 70× in total.
70.3 times more demand than shares on offer
populated partly populated we hold nothing here — the tab says why
The issuer’s own summary of outstanding legal proceedings — SEBI requires this table in every prospectus. Counts and amounts are as disclosed; the disclosed aggregate at stake is ₹79 Cr.
| Against | Criminal | Tax | Other material | Amount at stake |
|---|---|---|---|---|
| The company | 2 | 11 | 0 | ₹51 Cr |
| Directors | 0 | 1 | 0 | ₹4.6 Cr |
| Promoters | 0 | 1 | 0 | ₹4.6 Cr |
| Subsidiaries | 3 | 7 | 0 | ₹19 Cr |
| Group companies | 0 | 0 | 0 | — |
Prognosys Medical (subsidiary) vs Budhaditya Chattopadhyay, Swaroop Ghosh & DBS Bank officials — misappropriation of ~₹261.50 million via forged GOI logo and fake tenders; ED summoned subsidiary director; credit of ₹11.80 million recovered, ₹50.00 million pending
Income Tax vs Bigtec (subsidiary) — demand notice dated Jun 11, 2025 for AY 2021-22 of ₹153.81 million; Bigtec asserts exemption from MAT and links to suo moto rectification of prior erroneous ₹164.50 million demand
Income Tax department vs Company — AY 2021-22 assessment order (Mar 27, 2026) alleging false entries; demand of ₹140.38 million revised to ₹99.29 million via rectification; appeal and stay pending
CGST Audit-II Commissionerate, Pune vs Company — order dated Dec 12, 2025 directing payment of ₹81.29 million + ₹38.91 million GST plus ₹12.02 million penalty and interest (Apr 2026 writ before Bombay HC at Goa pending)
Income Tax vs Sriram Natarajan (Promoter/ED/CEO) — AY 2016-17 demand of ₹57.54 million; disallowance of ₹189.39 million short-term capital loss and ₹8.35 million expenditure; CIT(A) dismissed appeal Dec 19, 2025; ITAT appeal and penalty show-cause pending
All amounts stated in ₹ million in prospectus; converted to ₹ crore (1 crore = 10 million). Total_amount_cr derived as sum of bucket amounts (₹507.81m + ₹46.03m + ₹46.03m + ₹191.79m = ₹745.63m = ₹74.563 crore); however Directors and Promoters buckets reflect the same Sriram Natarajan matter, so excluding duplication total is ₹74.563 crore. Director/Promoter ₹46.03m overlap also noted. Grand total not explicitly stated in the text.. Outstanding means unresolved — a listed case is an exposure, not a verdict.
What the issuer and the exchanges published. Everything else on this tab is read out of these.
The full prospectus — business, financials, risk factors and litigation.
Which institutions were allotted shares before bidding opened, and how many.
Where physical applications could be submitted.
The issuer's own "basis of issue price": the earnings multiples it is asking for, and the peer companies it chose to compare itself against.
The full prospectus — business, financials, risk factors and litigation.
